NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Istituto Oncologico Veneto IRCCS
Global Coalition for Adaptive Research
Case Comprehensive Cancer Center
Bayer
Istituto Oncologico Veneto IRCCS